David Dai

Stock Analyst at UBS

(0)
# 4992
Out of 5,297 analysts
23
Total ratings
11.11%
Success rate
-34.68%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
NUVL Nuvalent
Upgrades: Buy
100 100
70.66 41.52% 2 Mar 14, 2025
KURA Kura Oncology
Maintains: Buy
27 14
6.54 114.07% 2 Mar 6, 2025
IMCR Immunocore Hldgs
Initiates Coverage On: Sell
24
29.46 -18.53% 1 Oct 24, 2024
BPMC Blueprint Medicines
Initiates Coverage On: Neutral
88
89.88 -2.09% 1 Oct 24, 2024
CATX Perspective Therapeu...
Initiates Coverage On: Buy
20
2.08 861.54% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
35
11.41 206.75% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
43.09 67.09% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
28.35 143.39% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
16.3 206.75% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
17
3.54 380.23% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
30
7.81 284.12% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
22.38 168.1% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
12.95 185.71% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.73 3735.62% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
14.02 185.31% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
1.22 3178.69% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
1.93 2490.67% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
41.1 26.52% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017